MaRS tenant draws kudos for migraine drug

Windhover Information Inc. — one of the world’s leaders in health-care strategy, industry trends and medical start-up analysis — has selected a migraine compound in development by a MaRS tenant as one of its Top 10 most promising neuroscience projects available for strategic partnering.

NeurAxon Inc., a tenant at MaRS since 2005, develops next-generation pain therapeutics. Its novel drug for treatment of migraine with aura, known as NXN-188, was tapped as one of the Top 10 most promising projects out of hundreds evaluated.

“We are extremely proud that NXN-188 has been selected as one of the Top 10 neuroscience projects available for partnering, further recognizing nNOS (neuronal nitric oxide synthase) inhibition as a fundamentally new mechanism to address very significant unmet needs and markets for a broad range of pain indications,” said NeurAxon CEO Dr. Lawrence Bloch.

As a selected company, NeurAxon has been invited to present data on NXN-188 at Windhover’s Therapeutic Area Parnerships conference taking place November 3-5, 2008, in Philadelphia.

Read NeurAxon’s news release here: “NeurAxon’s NXN-188 Named One of 10 Most Promising Neuroscience Projects by Windhover”.

Related Blogs

 

Clients wow at BioPartnering
Our life sciences and health care practice took three MaRS clients on the road to Vancouver last month to attend the 2011 BioPartnering North America (BPNA) meeting, the first major life sciences bus

Just because it's new, doesn't make it better
Ibuprofen 400 mg used with permission from Daisy The Fall season of the MaRS Drug Discovery Discussion Group launched this week with resident CSO, Dr. Ed Nemeth of NPS Pharmaceuticals, talking about

Why the US mid-term elections matter to the Canadian pharma industry
Take the Pill, originally uploaded by messyatwork The upcoming US Congress and Senate mid-term elections will have far-reaching, unforeseen consequences, whatever the result may be. The President a

The future of medicine's so bright
Imagine a world where… drugs work reliably no one ever gets sick from their prescriptions harmful properties are designed out of all new drugs critically-ill patients entering the ICU expect a po

The hope for a personalized approach
During a recent haircut, my hairdresser described my cut to a trainee as “a layered bob, but not really.”  I suggested calling it “The June.”  He then explained that it was indeed a haircut

Preventing type two diabetes
We’ve had several blogs on the topic of prevention of type two diabetes (T2D) over the past few years (see Want to live longer,  Want to live (even) longer and How to avoid diabetes).  The re

Tags: clients, drug development, health care, pharma, tenants, therapeutics